Aetna Members: You may have received a letter stating that The Dermatology of Indiana is no longer in-network, this is NOT accurate information.
Please contact your insurance if you have any questions or concerns. We look forward to continuing to serve your dermatology needs.

2016

Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
18 Years and Older
Phase: Phase 3
Start Date: February 2016
End Date: September 2017

Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
18 Years and Older
Phase: Phase 3
Start Date: February 2016
End Date: July 2018

Acne Vulgaris
Sponsor: Cassiopea SpA
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
9 Years and Older
Phase: Phase 3
Start Date: March 2016
End Date: December 2017

Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face
18 Years and Older
Phase: Phase 2
Start Date: March 2016
End Date: September 2016

Atopic Dermatitis
Sponsor: Pfizer
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
18-75 Years
Phase: Phase 2
Start Date: April 2016
End Date: May 2017

Plaque Psoriasis
Sponsor: Eli Lilly and Company
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
18-75 Years
Phase: Phase 2
Start Date: September 2016
End Date: February 2019